journal
MENU ▼
Read by QxMD icon Read
search

Journal of Thoracic Oncology

journal
https://www.readbyqxmd.com/read/29129758/impact-of-nivolumab-versus-docetaxel-on-health-related-quality-of-life-and-symptoms-in-patients-with-advanced-squamous-non-small-cell-lung-cancer-results-from-the-checkmate-017-study
#1
Martin Reck, Fiona Taylor, John R Penrod, Michael DeRosa, Laura Morrissey, Homa Dastani, Lucinda Orsini, Richard J Gralla
INTRODUCTION: In the phase III CheckMate 017 study, nivolumab prolonged overall survival versus docetaxel in previously treated patients with advanced squamous non-small cell lung cancer (NSCLC). Study objectives included health-related quality of life (HRQoL) and symptom assessments. METHODS: Patients serially completed Lung Cancer Symptom Scale (LCSS) and European Quality of Life Five Dimensions (EQ-5D) questionnaires. The LCSS average symptom burden index (ASBI; mean score for six lung cancer-specific symptoms; range, 0-100), LCSS 3-item global index, EQ-5D utility index, and EQ-5D visual analog scale scores were analyzed...
November 9, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/29128428/clinical-and-translational-implications-of-ret-rearrangements-in-non-small-cell-lung-cancer
#2
REVIEW
Roberto Ferrara, Nathalie Auger, Edouard Auclin, Benjamin Besse
Since the discovery in 2012 of RET rearrangements in non-small cell lung cancer (NSCLC), at least 12 different fusion variants have been identified, with KIF5B-RET being the most frequent and the best characterized. Unlike ALK and ROS1 rearrangements, RET fusion genes cannot be adequately detected by immunohistochemistry, although fluorescence in situ hybridization and reverse transcriptase PCR are fully complementary diagnostic tools. In large retrospective studies, RET rearrangements correlate with adenocarcinoma histology, never-smoking status, younger age, more advanced stage disease, potentially higher chemo-sensitivity (in particular to pemetrexed-based regimens), and coexistence of other genomic alterations...
November 8, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/29128427/osimertinib-and-cabozantinib-combinatorial-therapy-in-an-egfr-mutant-lung-adenocarcinoma-patient-with-multiple-met-secondary-site-mutations-after-resistance-to-crizotinib
#3
Jin Kang, Hua-Jun Chen, Zheng Wang, Jing Liu, Bing Li, Tengfei Zhang, Zhenfan Yang, Yi-Long Wu, Jin-Ji Yang
No abstract text is available yet for this article.
November 8, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/29127023/interobserver-variation-among-pathologists-and-refinement-of-criteria-in-distinguishing-separate-primary-tumours-from-intrapulmonary-metastases-in-lung
#4
Andrew G Nicholson, Kathleen Torkko, Patrizia Viola, Edwina Duhig, Kim Geisinger, Alain C Borczuk, Kenzo Hiroshima, Ming S Tsao, Arne Warth, Sylvie Lantuejoul, Prudence A Russell, Erik Thunnissen, Alberto Marchevsky, Mari Mino-Kenudson, Mary Beth Beasley, Johan Botling, Sanja Dacic, Yasushi Yatabe, Masayuki Noguchi, William D Travis, Keith Kerr, Fred R Hirsch, Lucian R Chirieac, Ignacio I Wistuba, Andre Moreira, Jin-Haeng Chung, Teh Ying Chou, Lukas Bubendorf, Gang Chen, Giuseppe Pelosi, Claudia Poleri, Frank C Detterbeck, Wilbur A Franklin
Multiple tumor nodules (MTNs) are seen with increasing frequency in clinical practice. Based on the 2015 WHO classification of lung tumors, we assessed the reproducibility of the comprehensive histologic assessment (CHA) to distinguish second primary lung cancers (SPLC) from intrapulmonary metastases (IPM), looking for the most distinctive histological features. An international panel of lung pathologists reviewed a scanned sequential cohort of 126 tumors from 48 patients, recorded an agreed set of histologic features, including tumor typing and predominant pattern of adenocarcinoma, thereby opining whether the case was SPLC, IPM or a combination...
November 7, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/29127022/genetic-and-immune-profiles-of-solid-predominant-lung-adenocarcinoma-reveal-potential-immunotherapeutic-strategies
#5
Zhong-Yi Dong, Chao Zhang, Yu-Fa Li, Jian Su, Zhi Xie, Si-Yang Liu, Li-Xu Yan, Zhi-Hong Chen, Xue-Ning Yang, Jun-Tao Lin, Hai-Yan Tu, Jin-Ji Yang, Qing Zhou, Yue-Li Sun, Wen-Zhao Zhong, Yi-Long Wu
BACKGROUND: Subtype classification of lung adenocarcinoma (LUAD) divides different survivals and therapeutic vulnerabilities, while the underlying molecular mechanism is little to be known. This study sought to determine the genetic and immune profiles of histologic subtypes and identify the evidence for adjuvant immunotherapy. PATIENTS AND METHODS: We performed an integrated analysis on multidimensional data from a discovery set including cohorts of The Cancer Genome Atlas (TCGA) and the Broad set from the LUAD public database, and a validation set from the Guangdong Lung Cancer Institute (GLCI)...
November 7, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/29113950/reviewing-recist-in-the-era-of-prolonged-and-targeted-therapy
#6
REVIEW
Rustain L Morgan, D Ross Camidge
Accurate assessment of disease response is the foundation of therapeutic trails, which is why the Response Evaluation Criteria in Solid Tumors (RECIST) criteria serves as an international standard investigators can utilize when examining patient outcomes. Nine years after the initial RECIST criteria were released, an update, RECIST 1.1, was published to improve on initial criteria and address technologic advancements in imaging. Since then advancements in both standard clinical and trial practices, combined with improvements in our understanding of cancer biology have resulted in the identification of a number of limitations of the current RECIST 1...
November 4, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/29113949/dysregulated-expression-of-the-microrna-mir-137-and-its-target-yb-1-contribute-to-the-invasive-characteristics-of-malignant-pleural-mesothelioma
#7
Thomas G Johnson, Karin Schelch, Yuen Y Cheng, Marissa Williams, Kadir H Sarun, Michaela B Kirschner, Steven Kao, Anthony Linton, Sonja Klebe, Brian C McCaughan, Ruby Cy Lin, Christine Pirker, Walter Berger, Annette Lasham, Nico van Zandwijk, Glen Reid
BACKGROUND: Malignant pleural mesothelioma (MPM) is an aggressive malignancy linked to asbestos exposure. On a genomic level, MPM is characterised by frequent chromosomal deletions of tumour suppressors, including microRNAs. MiR-137 plays a tumour suppressor role in other cancers, so the aim of this study was to characterise it and its target Y-box binding protein-1 (YB-1) in MPM. BASIC PROCEDURES: Expression, methylation and copy number status of miR-137 and its host gene MIR137HG were assessed by PCR...
November 4, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/29102694/kif5b-met-gene-rearrangement-with-robust-anti-tumor-activity-in-response-to-crizotinib-in-lung-adenocarcinoma
#8
Jang Ho Cho, Bo Mi Ku, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn
No abstract text is available yet for this article.
November 1, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/29101058/increased-response-rates-to-salvage-chemotherapy-administered-after-pd-1-pd-l1-inhibitors-in-patients-with-non-small-cell-lung-cancer
#9
Song Ee Park, Se Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park, Jong-Mu Sun
INTRODUCTION: While PD-1/PD-L1 inhibitors have shown some efficacy in treating advanced non-small cell lung cancer (NSCLC), their benefits are limited to only a subset of patients. Advanced NSCLC is generally treated with a chemotherapy and immunotherapy series. Here we evaluated whether PD-1/PD-L1 inhibitors affect the anti-tumor effects of salvage chemotherapy administered after immunotherapy (SCAI) in patients with NSCLC. METHODS: This study included patients with available SCAI response data...
October 31, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/29101057/cost-effectiveness-of-osimertinib-for-egfr-mutation-positive-non-small-cell-lung-cancer-after-progression-of-first-line-egfr-tki-therapy
#10
Bin Wu, Xiaohua Gu, Qiang Zhang
INTRODUCTION: To investigate the cost-effectiveness of osimertinib for the treatment of advanced non-small-cell lung cancer (NSCLC) with an epidermal growth factor receptor (EGFR) T790M mutation after the failure of first-line EGFR-tyrosine kinase inhibitor (EGFR-TKI) therapy. METHODS: A mathematical model was established by combining a decision tree and the Markov approach to project the cost-effectiveness of osimertinib for the treatment of patients who harbor an EGFR T790M mutation compared to that of standard chemotherapy, who had disease progression after first-line EGFR-TKI therapy with or without metastases to the central nervous system...
October 31, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/29101056/combined-small-cell-carcinoma-of-the-lung-is-it-a-single-entity
#11
Xiaoliang Zhao, Justine N McCutcheon, Bhaskar Kallakury, Joeffrey J Chahine, Drew Pratt, Mark Raffeld, Yulong Chen, Changli Wang, Giuseppe Giaccone
BACKGROUND: Small-cell lung carcinoma (SCLC) accounts for 15-20% of all lung cancers, with combined SCLC (CSCLC) comprising 2-5%. Little is known about the clinical characteristics and molecular changes associated with the various histologic components. METHODS: 205 SCLC cases were resected between 2005-2015. Clinical and pathologic features were analyzed. All CSCLC cases were confirmed by histology and immunohistochemistry. The individual components were microdissected using a novel automated dissection system and DNA was extracted and subjected to targeted exome sequencing...
October 31, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/29097253/brms1-expression-in-surgically-resected-lung-adenocarcinoma-predicts-future-metastases-and-is-associated-with-a-poor-prognosis
#12
Peter R Bucciarelli, Kay See Tan, Neel P Chudgar, Whitney Brandt, Joseph Montecalvo, Takashi Eguchi, Yuan Liu, Rania Aly, William D Travis, Prasad S Adusumilli, David R Jones
INTRODUCTION: Expression of breast cancer metastasis suppressor 1 (BRMS1) is decreased in non-small cell lung cancer cells and tumors. We hypothesized that intratumoral BRMS1 expression is associated with lung adenocarcinoma (LUAD) histologic subtypes and overall survival (OS) and disease-free survival (DFS) in patients undergoing resection for early-stage LUAD. METHODS: Patients (n=1030) who underwent complete resection for LUAD with tissue available for histologic evaluation were identified...
October 30, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/29107016/chimeric-antigen-receptor-car-t-cell-therapy-for-thoracic-malignancies
#13
REVIEW
Stefan Kiesgen, Leonardo Chicaybam, Navin K Chintala, Prasad S Adusumilli
Chimeric antigen receptor (CAR) T cells are patient T cells that are transduced with genetically engineered synthetic receptors to target a cancer cell surface antigen. The remarkable clinical response rates achieved by adoptive transfer of T cells that target CD19 in patients with leukemia and lymphoma have led to a growing number of clinical trials exploring CAR T-cell therapy for solid tumors. Herein, we review the evolution of adoptive T-cell therapy, highlight advances in CAR T-cell therapy for thoracic malignancies, and summarize the targets being investigated in clinical trials for patients with lung cancer, malignant pleural mesothelioma, and esophageal cancer...
October 26, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/29079455/molecular-and-histopathological-characterization-of-the-tumor-immune-microenvironment-in-advanced-stage-of-malignant-pleural-mesothelioma
#14
Namrata S Patil, Luisella Righi, Hartmut Koeppen, Wei Zou, Stefania Izzo, Federica Grosso, Roberta Libener, Marco Loiacono, Valentina Monica, Consuelo Buttigliero, Silvia Novello, Priti S Hegde, Mauro Papotti, Marcin Kowanetz, Giorgio V Scagliotti
INTRODUCTION: Malignant pleural mesothelioma (MPM) is a rare, highly aggressive, relatively chemo- and radio-resistant malignancy with limited therapeutic options. Our objective was to investigate the prevalence of PD-L1 and the characteristics of immune environment in this disease. METHODS: A total of 99 archival tumors from advanced stage MPM were immunohistochemically tested in parallel for PD-L1 in two different laboratories; and 87 of these were profiled for immune gene expression profiling by NanoString analysis for 800 genes...
October 24, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/29056534/comorbidity-in-lung-cancer-a-prospective-cohort-study-of-self-reported-versus-register-based-comorbidity
#15
Birgitte Sandfeld-Paulsen, Peter Meldgaard, Ninna Aggerholm-Pedersen
PURPOSE: Comorbidity is a debated prognosticator in lung cancer. Results are conflicting; and the variety in study designs and inclusion criteria hampers direct comparison of available studies. So far, methods for data generation on lung cancer comorbidity have attracted little attention. We evaluated if self-reported comorbidity and register-based comorbidity are of comparable quality. METHODS: In a prospective study, we evaluated paired datasets on self-reported versus register-based comorbidity to detect if any data asymmetry cold be related to the data collection methods...
October 19, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/29042270/regression-of-para-neoplastic-rash-following-lung-cancer-chemotherapy
#16
David J Pinato, Thomas Newsom-Davis
No abstract text is available yet for this article.
October 14, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/29024756/treatment-strategies-and-prognostic-factors-of-limited-stage-primary-small-cell-carcinoma-of-the-esophagus
#17
Lei Xu, Yin Li, Xianben Liu, Haibo Sun, Ruixiang Zhang, Jianbo Zhang, Yan Zheng, Zongfei Wang, Shilei Liu, Xiankai Chen
INTRODUCTION: Primary small cell carcinoma of the esophagus (PSCCE) is characterized by high malignancy, early metastasis and poor prognosis. This retrospective study aimed to review the clinical characteristics of patients with limited-stage PSCCE and determine the relevant prognostic factors and optimal treatment strategies. METHODS: We retrospectively evaluated 152 consecutive patients with limited-stage PSCCE between January 2007 and December 2015. Prognostic factors were analyzed using univariate analysis and a Cox regression model...
October 9, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28989040/molecular-adequacy-of-image-guided-rebiopsies-for-molecular-retesting-in-advanced-non-small-cell-lung-cancer-a-single-centre-experience
#18
Nadza Tokaca, Sarah Barth, Mary O'Brien, Jaishree Bhosle, Nicos Fotiadis, Andrew Wotherspoon, Lisa Thompson, Sanjay Popat
INTRODUCTION: In the era of biomarker-driven systemic therapy for advanced non-small cell lung cancer (NSCLC), the role of routine repeated biopsies for decision-making, outside EGFR mutant disease, remains unproven. We report our centre's experience of safety and adequacy for molecular retesting of tumour material obtained from image-guided lung rebiopsies in NSCLC. METHODS: We performed a retrospective case-note analysis of patients undergoing image-guided lung rebiopsies at a single cancer centre between 2011-14...
October 5, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28989039/first-line-osimertinib-in-patients-with-treatment-naive-somatic-or-germline-egfr-t790m-mutant-metastatic-nsclc
#19
Katerina Ancevski Hunter, David M Friedland, Liza C Villaruz, Timothy F Burns
No abstract text is available yet for this article.
October 5, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28989038/risk-of-second-lung-cancer-in-patients-with-previously-treated-lung-cancer-analysis-of-surveillance-epidemiology-and-end-results-seer-data
#20
Manish K Thakur, Julie J Ruterbusch, Ann G Schwartz, Shirish M Gadgeel, Jennifer L Beebe-Dimmer, Antoinette J Wozniak
BACKGROUND: The risk of developing a second primary lung cancer (SPLC) after the treatment of an initial primary lung cancer (IPLC) is around 1-2 % per patient per year. Present screening/surveillance guidelines do not adequately address this particular patient population. PATIENTS AND METHODS: We retrospectively reviewed patients in the Surveillance, Epidemiology, and End Results (SEER) data base from 1992 to 2007 to assess the frequency of occurrence of SPLC with regard to multiple patient demographics and calculated Standardized Incidence Ratios (SIRs)...
October 5, 2017: Journal of Thoracic Oncology
journal
journal
41363
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"